Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1170-1178

  Corsetti, James P ^a   Ryan, Dan ^a   Moss, Arthur J ^a   Mccarthy, Jeanette J ^b   Goldenberg, Ilan ^a   Zareba, Wojciech ^a   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

C reactive protein; HDL cholesterol; Inflammation; Oxidative stress; Thrombospondin 4

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOSPONDIN; THROMBOSPONDIN 4; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ETHNICITY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; THBS4 GENE; THROMBOGENESIS;

AGED; ARTERITIS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY DISEASE; DNA MUTATIONAL ANALYSIS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROGNOSIS; RECURRENCE; RISK; THROMBOSPONDINS;

EID: 82555193688     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0206     Document Type: Article

References (31)

1. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2010; 12: 343-348.
2. Shao B, Oda M, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23: 447-454.
3. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-434.
4. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.
5. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metabol Cardiovasc Dis 2006; 16: 371-386.
6. Corsetti JP, Gansevoort RT, Sparks CE, et al. HDL Protection against Primary Cardiac Risk is Lost with Inflammation. Eur J Clin Invest 2010; 40: 483-489.
7. Corsetti JP, Gansevoort RT, Navis GJ, et al. LPL Polymorphism (D9N) Predicts Cardiovascular Disease Risk Directly and Through Interaction with CETP Polymorphism (TaqIB) in Women with High HDL Cholesterol and CRP. Atherosclerosis 2011; 214: 373-376.
8. Corsetti JP, Ryan D, Rainwater DL, et al. CETP Polymorphism (TaqIB) Associates with Risk in Postinfarction Patients with High HDL Cholesterol and High CRP Levels. Arterioscler Thromb Vasc Biol 2010; 30: 1657-1664.
9. Corsetti JP, Ryan D, Moss AJ, et al. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 2007; 196: 461-468.
10. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-2644.
11. Stenina OI, Topol EJ, Plow EF. Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 1886-1894.
12. Frolova E, Pluskota E, Krukovets I, et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res 2010; 107: 1313-1325.
13. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary Risk. J Am Med Assoc 2008; 299: 2777-2788.
14. Dullaart RPF, Sluiter W. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 2008; 9: 747-763.
15. Guzik TJ, West NEJ, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-1747.
16. Nakano T, Matsunaga S, Nagata A, et al. NAD(P)H oxidase p22phox gene C242T polymorphism and lipoprotein oxidation. Clin Chim Acta 2003; 335: 101-107.
17. Corsetti JP, Zareba W, Moss AJ, et al. Serum Glucose and Triglyceride Determine High-Risk Subgroups in Non-Diabetic Postinfarction Patients. Atherosclerosis 2005; 183: 293-300.
18. Corsetti JP, Rainwater DL, Moss AJ, et al: High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-1338.
19. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genetic Analysis 1999; 14: 143-149.
20. Goldenberg I, Moss AJ, Block R, et al. Polymorphism in the cholesteryl ester transfer protein gene and the risk of early onset myocardial infarction among cigarette smokers. Ann Noninv Electrocardiol 2007; 12: 364-374.
21. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
22. Badimon L, Storey, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl 1): S34-S42.
23. Zareba W, Pancio G, Moss AJ, et al. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. Thromb Haemost 2001; 86: 791-799.
24. Koch W, Hoppmann P, de Waha A, et al. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. Hum Mol Gen 2008; 17: 1120-1126.
25. Stenina OI, Ustinov V, Krukovets I, et al. Polymorphisms A387P in thrombospondin- 4 and N700S in thrombospondin-1 perturb calcium binding sites. Faseb J 2005; 19: 1893-1895.
26. Stenina OI, Byzova TV, Adams JC, et al. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004; 36: 1013-1030.
27. Stenina OI, Shailesh YD, Krukovets I, et al. Thrombospondin-4 and its variants expression and differential effects on endothelial cells. Circulation 2003; 108: 1514-1519.
28. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55: 229-238.
29. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263: 517-527.
30. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-1364.
31. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-378.